Biomarkers /
MYH11
Overview
Myosin, heavy chain 11, smooth muscle (MYH11) is a gene that encodes a protein that functions as a smooth muscle myosin - a major contractile protein that converts chemical energy to mechanical energy via ATP hydrolysis. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
MYH11 is altered in 0.28% of all cancers with high grade ovarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MYH11 are MYH11 Fusion (0.03%), MYH11 G1238R (0.43%), MYH11 T1911M (0.70%), MYH11-CBFB Fusion (0.03%), and MYH11 A1076V (0.22%) [3].
Clinical Trials
Significance of MYH11 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.